|H M Mk||Endogenous||28, 30||Rabbit IgG|
Western blot analysis of extracts from various cell lines using PSMB7 (E1L5H) Rabbit mAb.Learn more about how we get our images
Western blot analysis of extracts from HeLa cells, untreated (-) or treated with Human Interferon-γ (hIFN-γ) #8901 (100 ng/ml, 72 hr; +), using PSMB7 (E1L5H) Rabbit mAb (upper) and GAPDH (D16H11) XP® Rabbit mAb #5174 (lower).Learn more about how we get our images
For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody datasheet or product webpage for recommended antibody dilution.
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised November 2013
Reprobing of an existing membrane is a convenient means to immunoblot for multiple proteins independently when only a limited amount of sample is available. It should be noted that for the best possible results a fresh blot is always recommended. Reprobing can be a valuable method but with each reprobing of a blot there is potential for increased background signal. Additionally, it is recommended that you verify the removal of the first antibody complex prior to reprobing so that signal attributed to binding of the new antibody is not leftover signal from the first immunoblotting experiment. This can be done by re-exposing the blot to ECL reagents and making sure there is no signal prior to adding the next primary antibody.
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalently purified water.
posted June 2005
revised June 2016
Protocol Id: 263
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
PSMB7 (E1L5H) Rabbit mAb recognizes endogenous levels of total PSMB7 protein. This antibody reacts with precursor and mature forms of PSMB7, but does not cross-react with PSMB10.
Human, Mouse, Monkey
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys237 of human PSMB7 protein.
The 26S proteasome is a highly abundant proteolytic complex involved in the degradation of ubiquitinated substrate proteins. It consists largely of two sub-complexes, the 20S catalytic core particle (CP) and the 19S/PA700 regulatory particle (RP) that can cap either end of the CP. The CP consists of two stacked heteroheptameric β-rings (β1-7) that contain three catalytic β-subunits and are flanked on either side by two heteroheptameric α-rings (α1-7). The RP includes a base and a lid, each having multiple subunits. The base, in part, is composed of a heterohexameric ring of ATPase subunits belonging to the AAA (ATPases Associated with diverse cellular Activities) family. The ATPase subunits function to unfold the substrate and open the gate formed by the α-subunits, thus exposing the unfolded substrate to the catalytic β-subunits. The lid consists of ubiquitin receptors and DUBs that function in recruitment of ubiquitinated substrates and modification of ubiquitin chain topology (1,2). Other modulators of proteasome activity, such as PA28/11S REG, can also bind to the end of the 20S CP and activate it (1,2).
The core particle exhibits three distinct enzymatic activities, each catalyzed by a separate protein subunit. The constitutively expressed PSMB5, PSMB7, and PSMB6 subunits provide chymotrypsin-like, trypsin-like, and caspase-like activities, respectively. These catalytic subunits belong to the amino-terminal nucleophile (Ntn) hydrolase family and are characterized by a single-residue active site. The catalytic β-subunits are synthesized with amino-terminal propeptides, which are removed at the final step of proteasome biogenesis to expose the catalytic threonine residues (3). In immune cells involved in antigen presentation, the constitutively expressed PSMB6, PSMB7, and PSMB5 subunits are replaced by three highly homologous, induced β-subunits to form the immunoproteasome (4,5). PSMB7 is downregulated at the protein level by IFN-γ and replaced by PSMB10 to remodel the proteolytic specificity of the proteasome for more appropriate immunological processing of endogenous antigens (6). Research studies show that PSMB7 expression is upregulated in human colon adenocarcinomas and suggest that high PSMB7 expression may serve as a potential prognostic marker in breast cancer (7,8).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. XP is a registered trademark of Cell Signaling Technology, Inc. Tween is a registered trademark of ICI Americas, Inc.
Explore pathways related to this product.
|13207S||100 µl (10 western blots)||$ 255.0|